By Nigel Somerville, the Deputy Sheriff of AIM | Friday 21 August 2020
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
It was announced this morning that AIM-listed Advanced Oncotherapy (AVO) has drawn down an initial $10 million on its secured convertible loan package totalling $30 million with Nerano Pharm – a financing vehicle wholly owned by significant shareholder Seamus Mulligan. So is this a death spiral, and what’s the catch?
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.
Filed under:
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Time left: 12:54:33